<DOC>
	<DOCNO>NCT02597270</DOCNO>
	<brief_summary>The purpose study describe genetic diversity Hepatitis C virus ( HCV ) NS3/4a protease NS5A protein HCV participants chronic disease naive-drug previously fail double therapy ( Peg-interferon Ribavirin ) identify frequency natural polymorphism HCV NS3/4a protease NS5A protein associate direct-acting antiviral ( DAAs ) -resistance .</brief_summary>
	<brief_title>An Observational/Non-interventional , Study NS3/4a Protease NS5A Protein Hepatitis C Virus Brazilian Participants With Chronic HCV Infection</brief_title>
	<detailed_description>This multicenter , observational/non-interventional , cross-sectional study describe genetic diversity identify natural polymorphism HCV NS3/4a protease NS5A protein hepatitis C virus Brazilian participant chronic HCV infection . Brazilian participant Genotype 1 HCV infection treatment naive participant previously fail double therapy ( Peg-interferon-α Ribavirin ) include trial constitute trial population .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Participants mono infect chronic Hepatitis C infection ( genotype 1 ) , include naive patient previously fail double therapy ( Peginterferonα Ribavirin ) There restriction fibrosis stage clinical liver disease There restriction comorbidities Male female participant age &gt; =18 year Participants fail triple therapy use protease inhibitor Participants coinfections ( i.e . Human immunodeficiency virus , Hepatitis B virus ) Participants agree sign write informed consent Participants take part interventional clinical trial investigational agent ( i.e . noncommercialized agent ) interventional clinical trial sponsor Johnson &amp; Johnson</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hepatitis C virus</keyword>
</DOC>